公开(公告)号：EP3232200A1

公开(公告)日：2017-10-18

申请号：EP16382167.1

申请日：2016-04-12

申请人： Institut Catalá De Ciencies Cardiovasculars (ICCC) ,  Consejo Superior De Investigaciones Científicas

发明人： BADIMON MAESTRO, Lina ,  CUBEDO RÀFOLS, Judit ,  PADRÓ CAPMANY, Teresa

IPC分类号： G01N33/68

CPC分类号： G01N33/6893 ,  G01N2333/775 ,  G01N2400/00 ,  G01N2800/2871 ,  G01N2800/324

摘要： The invention relates to methods for the diagnosis of ischemia or ischemic tissue damage, methods for predicting the progression of ischemia in a patient having suffered an ischemic event, for determining the prognosis of a patient having suffered an ischemic event and for determining the risk that a patient suffering from stable coronary disease suffers a recurrent ischemic event based on the detection of the levels of glycosylated Apo J. The invention relates as well to a method for the determination of glycosylated Apo J in a sample.

摘要翻译： 本发明涉及缺血或缺血性组织损伤的诊断方法，预测缺血事件患者缺血进展的方法，用于确定患有缺血事件的患者的预后以及用于确定 患有稳定型冠心病的患者基于检测糖基化Apo J的水平而患有复发缺血事件。本发明还涉及测定样品中糖基化Apo J的方法。

公开(公告)号：EP3219326A1

公开(公告)日：2017-09-20

申请号：EP16382111.9

申请日：2016-03-14

申请人： Institut Catalá De Ciencies Cardiovasculars (ICCC)

发明人： BADIMON MAESTRO, Lina ,  CUBEDO RÀFOLS, Judit ,  VILAHUR GARCÍA, Gemma ,  PADRÓ CAPMANY, Teresa

IPC分类号： A61K38/16 ,  A61K38/47 ,  A61P9/10

CPC分类号： C12Y301/01002 ,  A61K38/465

摘要： The present invention relates to pharmaceutical compositions comprising a compound selected from the group consisting of: a) a polypeptide of SEQ ID NO:1, b) a functionally equivalent variant of the polypeptide according to a), c) a polynucleotide encoding a) or b), d) a vector comprising a polynucleotide according to c), e) a cell capable of secreting into the medium a polypeptide according to a) or b), and f) a nanoparticle comprising the polypeptide according to a) or b) and a pharmaceutically acceptable excipient. The invention also relates to the use of said compounds or pharmaceutical compositions for treatment and/or prevention of ischemia injury or ischemia/reperfusion injury in a subject.

摘要翻译： 本发明涉及药物组合物，其包含选自以下的化合物：a）SEQ ID NO：1的多肽，b）a）的多肽的功能等同变体，c）编码a）或 b），d）包含根据c）的多核苷酸的载体，e）能够将根据a）或b）的多肽分泌到培养基中的细胞，以及f）包含根据a）或b）的多肽的纳米颗粒， 和药学上可接受的赋形剂。 本发明还涉及所述化合物或药物组合物用于治疗和/或预防受试者的局部缺血损伤或局部缺血/再灌注损伤的用途。